ERBB2 and breast carcinoma: Many studies have implicated SHC1 involvement in signaling by epidermal growth factor receptor-2 (HER-2), estrogen receptor (ER), and prolactin (PR) signaling, three well-established biological markers for prognosis and response to breast cancer therapy [3–5].